Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1182MR)

This product GTTS-WQ1182MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1182MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13926MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ6673MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ3861MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ7308MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ5303MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ6684MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ4017MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ4609MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW